InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans

Intercure ( (IL:INCR) ) has provided an update.

On February 19, 2026, InterCure reported preliminary 2025 results showing estimated revenue of NIS 265 million, up about 11% year on year, with nearly 20% growth in the second half and positive adjusted EBITDA for a twelfth consecutive half-year. The company ended 2025 with NIS 43 million in cash, resumed production, imports and sales at its war-damaged Nir Oz facility, launched more than 70 new GMP products, and began generating its first significant German-market revenues.

InterCure also advanced its expansion strategy in 2025 by entering a deal to acquire Botanico Ltd. to bolster access to premium U.S. genetics and cultivation technologies and by taking a 28% stake in Cannasoul R&D to deepen pharmaceutical research capabilities. Management emphasized the firm’s positioning to benefit from evolving cannabis regulations in Europe and the U.S., while pursuing war-damage compensation claims of NIS 251 million and maintaining production continuity amid Bazelet’s restructuring proceedings.

The most recent analyst rating on (IL:INCR) stock is a Sell with a ILs283.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.

More about Intercure

InterCure Ltd., operating as Canndoc, is a leading, profitable medical cannabis company based in Israel and listed on Nasdaq and TASE. Through its vertically integrated “seed-to-sale” model, GMP-certified pharmaceutical-grade products, and international partnerships, it targets fast-growing medical cannabis markets outside North America, leveraging a strong domestic footprint and expanding European presence.

Average Trading Volume: 104,513

Technical Sentiment Signal: Sell

Current Market Cap: ILs152.3M

For an in-depth examination of INCR stock, go to TipRanks’ Overview page.